Clinical Trials on Adenocarcinoma, Follicular

Total 10171 results

Seoul National University Hospital

Terminated

Effectiveness of Intraoperative Neuromonitoring of External Branch of Superior Laryngeal Nerve During Thyroid Surgery

Carcinoma, Papillary, Follicular

Korea, Republic of
National University Health System, Singapore

Completed

Aberrant Helix Pomatia Agglutinin Binding Glycan Expression in Follicular Thyroid Tumours

Follicular Thyroid Cancer

Singapore
National Cancer Institute (NCI)

Completed

Decitabine in Treating Patients With Metastatic Papillary Thyroid Cancer or Follicular Thyroid Cancer Unresponsive to Iodine I 131

Recurrent Thyroid Cancer | Stage IVA Follicular Thyroid Cancer | Stage IVA Papillary Thyroid Cancer | Stage IVB Follicular Thyroid Cancer | Stage IVB Papillary Thyroid Cancer | Stage IVC Follicular Thyroid Cancer | Stage IVC Papillary Thyroid Cancer

United States
University of Washington
National Cancer Institute (NCI); GlaxoSmithKline; National Comprehensive Cancer...

Completed

Iodine I 131 and Pazopanib Hydrochloride in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer Previously Treated With Iodine I 131 That Cannot Be Removed By Surgery

Recurrent Thyroid Cancer | Stage IVA Follicular Thyroid Cancer | Stage IVA Papillary Thyroid Cancer | Stage IVB Follicular Thyroid Cancer | Stage IVB Papillary Thyroid Cancer | Stage IVC Follicular Thyroid Cancer | Stage IVC Papillary Thyroid Cancer

United States
Memorial Sloan Kettering Cancer Center

Active, not recruiting

PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer

Thyroid Cancer, Follicular | Thyroid Cancer | Papillary Thyroid Cancer | Poorly Differentiated Thyroid Gland Carcinoma | Follicular Thyroid Cancer | Hurthle Cell Tumor | Hurthle Cell Thyroid Neoplasia

United States
Kenneth Ain
Celgene Corporation

Completed

REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid Carcinomas

Thyroid Neoplasms

United States
Grupo Espanol de Tumores Neuroendocrinos
MFAR

Active, not recruiting

Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial (DUTHY)

Metastatic Thyroid Cancer | Metastatic Thyroid Papillary Carcinoma | Metastatic Thyroid Follicular Carcinoma

Spain
National Cancer Institute (NCI)

Completed

Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine

Recurrent Thyroid Cancer | Stage IV Follicular Thyroid Cancer | Stage IV Papillary Thyroid Cancer

United States
National Taiwan University Hospital

Recruiting

Urinary Exosomal Biomarkers of Thyroglobulin and Galectin-3 for Prognosis and Follow-up in Patients of Thyroid Cancer

Thyroid Cancer | Papillary Thyroid Cancer | Follicular Thyroid Cancer

Taiwan
Assistance Publique Hopitaux De Marseille

Unknown

Psychological Impact of a Sophrological Accompaniment During the Announcement of Thyroid Cancer

Follicular Thyroid Cancer

France
National Cancer Institute (NCI)

Completed

Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy

Insular Thyroid Cancer | Recurrent Thyroid Cancer | Stage II Follicular Thyroid Cancer | Stage II Papillary Thyroid Cancer | Stage IV Follicular Thyroid Cancer | Stage IV Papillary Thyroid Cancer

United States
Mayo Clinic

Recruiting

Radioiodine Planar and a SPECT/CT Imaging With Iodine-123 for Evaluation of Follicular Thyroid Nodules Prior to Surgery

Thyroid Gland Follicular Carcinoma

United States
National Taiwan University Hospital

Recruiting

Correlation Between Various Urinary Exosomal Protein Biomarkers and Pathological Manifestation in Thyroid Follicular Neoplasm: Early and Pre-operative Diagnosis of Follicular Thyroid Cancer

Thyroid Cancer | Follicular Thyroid Cancer

Taiwan
National Cancer Institute (NCI)

Terminated

Sorafenib Tosylate in Treating Patients With Locally Advanced, Metastatic, or Locally Recurrent Thyroid Cancer

Insular Thyroid Cancer | Recurrent Thyroid Cancer | Stage IV Follicular Thyroid Cancer | Stage IV Papillary Thyroid Cancer | Anaplastic Thyroid Cancer | Stage III Follicular Thyroid Cancer | Stage III Papillary Thyroid Cancer

United States
National Cancer Institute (NCI)
Exelixis

Completed

Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer

Recurrent Thyroid Gland Carcinoma | Poorly Differentiated Thyroid Gland Carcinoma | Stage I Thyroid Gland Papillary Carcinoma | Stage II Thyroid Gland Papillary Carcinoma | Stage III Thyroid Gland Papillary Carcinoma | Tall Cell Variant Thyroid Gland Papillary Carcinoma | Stage I Thyroid Gland... and other conditions

United States
Medstar Health Research Institute
Pfizer

Completed

Sutent Adjunctive Treatment of Differentiated Thyroid Cancer (IIT Sutent)

Papillary Thyroid Cancer | Differentiated Thyroid Cancer | Follicular Thyroid Cancer

United States
National Taiwan University Hospital

Completed

Anaplastic Thyroid Cancer and Follicular Thyroid Cancer-derived Exosomal Analysis Via Treatment of Lovastatin and Vildagliptin and Pilot Prognostic Study Via Urine Exosomal Biological Markers in Thyroid Cancer Patients

Thyroid Cancer
The Catholic University of Korea

Completed

Hürthle Cell Carcinoma and Follicular Thyroid Carcinoma (HCC and FTC)

Huerthle Cell Carcinoma
Bhavana Konda
National Comprehensive Cancer Network

Active, not recruiting

Dabrafenib With or Without Trametinib in Treating Patients With Recurrent Thyroid Cancer

Insular Thyroid Cancer | Recurrent Thyroid Cancer | Papillary Thyroid Cancer | Follicular Thyroid Cancer

United States
National Cancer Institute (NCI)

Completed

Aflibercept in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy

Recurrent Thyroid Gland Carcinoma | Stage III Thyroid Gland Papillary Carcinoma | Stage IV Thyroid Gland Papillary Carcinoma | Stage III Thyroid Gland Follicular Carcinoma | Stage IV Thyroid Gland Follicular Carcinoma

United States
University of Washington
National Cancer Institute (NCI)

Completed

Sunitinib Malate in Treating Patients With Iodine-Refractory Recurrent or Metastatic Thyroid Cancer

Recurrent Thyroid Cancer | Thyroid Gland Medullary Carcinoma | Stage IVA Follicular Thyroid Cancer | Stage IVA Papillary Thyroid Cancer | Stage IVB Follicular Thyroid Cancer | Stage IVB Papillary Thyroid Cancer | Stage IVC Follicular Thyroid Cancer | Stage IVC Papillary Thyroid Cancer

United States
Massachusetts General Hospital
Eli Lilly and Company

Recruiting

Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC

Thyroid Carcinoma | Thyroid Cancer | Papillary Thyroid Cancer | Metastatic Thyroid Cancer | Follicular Thyroid Cancer | Unresectable Thyroid Gland Carcinoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Evaluation of 18F-TFB PET/CT Scan in Patients With Differentiated Thyroid Cancer

Differentiated Thyroid Gland Carcinoma | Thyroid Gland Follicular Carcinoma | Thyroid Gland Papillary Carcinoma

United States
H. Lee Moffitt Cancer Center and Research Institute

Terminated

Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer

Thyroid Cancer, Medullary | Thyroid Cancer | Papillary Thyroid Cancer | Differentiated Thyroid Cancer | Poorly Differentiated Thyroid Gland Carcinoma | Follicular Thyroid Cancer

United States
National Cancer Institute (NCI)

Completed

Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer

Insular Thyroid Cancer | Recurrent Thyroid Cancer | Stage II Follicular Thyroid Cancer | Stage II Papillary Thyroid Cancer | Stage IV Follicular Thyroid Cancer | Stage IV Papillary Thyroid Cancer | Thyroid Gland Medullary Carcinoma

United States
The First Affiliated Hospital of Xiamen University

Recruiting

Evaluation of 177Lu-DOTA-EB-FAPI in Patients With Metastatic Radioactive Iodine Refractory Thyroid Cancer

Refractory Thyroid Gland Carcinoma | Refractory Thyroid Gland Papillary Carcinoma | Refractory Thyroid Gland Follicular Carcinoma | Refractory Thyroid Gland Hurthle Cell Carcinoma

China
Emory University
Eisai Inc.

Terminated

Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer

Differentiated Thyroid Gland Carcinoma | Thyroid Gland Follicular Carcinoma | Thyroid Gland Papillary Carcinoma

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Active, not recruiting

Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer

Recurrent Thyroid Gland Carcinoma | Poorly Differentiated Thyroid Gland Carcinoma | Stage IV Thyroid Gland Follicular Carcinoma AJCC v7 | Stage IV Thyroid Gland Papillary Carcinoma AJCC v7 | Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7 | Stage IVA Thyroid Gland Papillary Carcinoma AJCC... and other conditions

United States
National Cancer Institute (NCI)

Completed

Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer

Refractory Differentiated Thyroid Gland Carcinoma | Unresectable Thyroid Gland Carcinoma | Refractory Thyroid Gland Papillary Carcinoma | Refractory Thyroid Gland Follicular Carcinoma | Refractory Thyroid Gland Hurthle Cell Carcinoma

United States, Canada
Massachusetts General Hospital

Completed

Pre-Operative Nodal Staging of Thyroid Cancer Using USPIO MRI: Preliminary Study

Papillary Carcinoma of Thyroid Gland | Metastatic Medullary Thyroid Cancer | Follicular Thyroid Cancer Lymph Node Metastasis

United States
Memorial Sloan Kettering Cancer Center

Completed

Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers

Thyroid Cancer, Papillary | Thyroid Cancer, Follicular | Thyroid Carcinoma | Thyroid Cancer | Thyroid Cancer (Follicular Cell) | BRAF V600E Mutation Positive

United States
Joseph Tuscano
National Cancer Institute (NCI); Genentech, Inc.; Pharmacyclics LLC.

Recruiting

Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma

Ann Arbor Stage II Follicular Lymphoma | Ann Arbor Stage III Follicular Lymphoma | Ann Arbor Stage IV Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma

United States
National Institute of Diabetes and Digestive and...

Recruiting

Studies on Tumors of the Thyroid

Thyroid Cancer | Papillary Thyroid Cancer | Hurthle Cell Thyroid Cancer | Tall Cell Variant Thyroid Cancer | Follicular Thyroid Cancer

United States
National Cancer Institute (NCI)

Active, not recruiting

Trametinib in Increasing Tumoral Iodine Incorporation in Patients With Recurrent or Metastatic Thyroid Cancer

Recurrent Thyroid Gland Carcinoma | Poorly Differentiated Thyroid Gland Carcinoma | Refractory Thyroid Gland Carcinoma | Stage IV Thyroid Gland Follicular Carcinoma AJCC v7 | Stage IV Thyroid Gland Papillary Carcinoma AJCC v7 | Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7 | Stage IVA Thyroid... and other conditions

United States
National Cancer Institute (NCI)

Completed

Tanespimycin in Treating Patients With Inoperable Locoregionally Advanced or Metastatic Thyroid Cancer

Recurrent Thyroid Cancer | Stage IV Follicular Thyroid Cancer | Stage IV Papillary Thyroid Cancer | Thyroid Gland Medullary Carcinoma

United States
National Cancer Institute (NCI)

Terminated

Rituximab and Oblimersen in Treating Patients With Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma

Stage III Grade 1 Follicular Lymphoma | Stage III Grade 2 Follicular Lymphoma | Stage III Grade 3 Follicular Lymphoma | Stage IV Grade 1 Follicular Lymphoma | Stage IV Grade 2 Follicular Lymphoma | Stage IV Grade 3 Follicular Lymphoma

United States
National Cancer Institute (NCI)
Celgene Corporation

Active, not recruiting

Rituximab, Lenalidomide, and Ibrutinib in Treating Patients With Previously Untreated Stage II-IV Follicular Lymphoma

Ann Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma | Ann Arbor Stage II Grade 3 Non-Contiguous... and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma

United States
Memorial Sloan Kettering Cancer Center
Fox Chase Cancer Center; Pharmacyclics LLC.

Terminated

Ibrutinib for Patients With Follicular Lymphoma Without Complete Response to Initial Chemoimmunotherapy

Follicular Lymphoma | Follicular Lymphoma, Grade 1 | Follicular Lymphoma, Grade 2 | Follicular Lymphoma Grade IIIa

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma

Grade 3a Follicular Lymphoma | Ann Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage III Grade 3 Follicular Lymphoma | Ann Arbor Stage...

United States
Olivia Newton-John Cancer Research Institute
Bristol-Myers Squibb; Barwon Health; Austin Health; Eastern Health; Fiona Stanley... and other collaborators

Recruiting

Treatment Of Newly-diagnosed Follicular Lymphoma With CELMoD BMS-986369, Rituximab +/- Nivolumab. (TOP-FLOR)

Follicular Lymphoma Stage II | Follicular Lymphoma Stage III | Follicular Lymphoma Stage IV

Australia
National Cancer Institute (NCI)

Completed

Lenalidomide and Rituximab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma

Ann Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma | Ann Arbor Stage II Grade 3 Non-Contiguous... and other conditions

United States
Fondazione Italiana Linfomi ONLUS

Completed

"MIRO" Molecularly Oriented Immuno-radio-therapy (FIL_MIRO)

Follicular Lymphoma, Grade 1 | Follicular Lymphoma, Grade 2 | Follicular Lymphoma Grade 3A

Italy
Heidelberg University
Roche Pharma AG

Active, not recruiting

Gazyvaro and Low Dose Radiotherapy in Early Stage Follicular Lymphoma (GAZAI)

Stage II Grade 1 Follicular Lymphoma | Stage II Grade 2 Follicular Lymphoma | Stage I Follicular Lymphoma Grade 1 | Stage II Follicular Lymphoma Grade 2

Germany
Epizyme, Inc.

Recruiting

Study of Tazemetostat Versus Placebo When Given in Combination With Lenalidomide and Rituximab in Participants With Relapsed/Refractory Follicular Lymphoma (SYMPHONY-1)

Follicular Lymphoma | Relapsed/Refractory Follicular Lymphoma | Refractory Follicular Lymphoma

United States, China, Spain, France, Taiwan, United Kingdom, Australia, Korea, Republic of, Canada, Italy, Hungary, Poland, Belgium, Germany
National Cancer Institute (NCI)

Active, not recruiting

Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Refractory Follicular Lymphoma | Grade 3a Follicular Lymphoma

United States, Canada, Singapore
National Cancer Institute (NCI)

Active, not recruiting

Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma

Grade 3a Follicular Lymphoma | Ann Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann Arbor Stage III Grade 3 Follicular Lymphoma | Ann Arbor Stage...

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer

Poorly Differentiated Thyroid Gland Carcinoma | Refractory Differentiated Thyroid Gland Carcinoma | Refractory Thyroid Gland Carcinoma | Follicular Variant Thyroid Gland Papillary Carcinoma | Tall Cell Variant Thyroid Gland Papillary Carcinoma | Differentiated Thyroid Gland Carcinoma | Thyroid... and other conditions

United States
Epizyme, Inc.
Ipsen

Not yet recruiting

A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation (Mandolin)

Follicular Lymphoma | Refractory Follicular Lymphoma
Mayo Clinic
National Cancer Institute (NCI)

Completed

Rituximab With or Without Yttrium Y-90 Ibritumomab Tiuxetan in Treating Patients With Untreated Follicular Lymphoma

Ann Arbor Stage I Grade 1 Follicular Lymphoma | Ann Arbor Stage I Grade 2 Follicular Lymphoma | Ann Arbor Stage III Grade 1 Follicular Lymphoma | Ann Arbor Stage III Grade 2 Follicular Lymphoma | Ann Arbor Stage IV Grade 1 Follicular Lymphoma | Ann Arbor Stage IV Grade 2 Follicular Lymphoma | Ann... and other conditions

United States

Clinical Trials on Adenocarcinoma, Follicular

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Morocco

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations